Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

GeneDx Holdings (WGSWW) Cost of Revenue (2020 - 2025)

GeneDx Holdings has reported Cost of Revenue over the past 6 years, most recently at $68.1 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $68.1 million for Q4 2025, up 285.22% from a year ago — trailing twelve months through Dec 2025 was $129.4 million (up 30.29% YoY), and the annual figure for FY2025 was $129.4 million, up 92.02%.
  • Cost of Revenue for Q4 2025 was $68.1 million at GeneDx Holdings, up from $23.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for WGSWW hit a ceiling of $168.6 million in Q4 2022 and a floor of $13.5 million in Q1 2023.
  • Median Cost of Revenue over the past 5 years was $27.9 million (2021), compared with a mean of $39.7 million.
  • Biggest five-year swings in Cost of Revenue: crashed 73.68% in 2024 and later surged 285.22% in 2025.
  • GeneDx Holdings' Cost of Revenue stood at $60.6 million in 2021, then soared by 178.19% to $168.6 million in 2022, then plummeted by 60.17% to $67.2 million in 2023, then crashed by 73.68% to $17.7 million in 2024, then surged by 285.22% to $68.1 million in 2025.
  • The last three reported values for Cost of Revenue were $68.1 million (Q4 2025), $23.5 million (Q3 2025), and $19.4 million (Q2 2025) per Business Quant data.